Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some therapeutic/clinical and mechanism claims align with the provided FDA label excerpts (asthma, EIB prevention, allergic rhinitis, CysLT1 receptor mechanism). However, multiple statements about antibiotic/non-antibiotic use, lack of bacterial efficacy, and antibiotic substitution are not supported by the supplied label sections.
Category Scores
Accurate Statements
Montelukast is used to treat asthma.
Supported by 1.1 Asthma (prophylaxis and chronic treatment of asthma).
Montelukast works by blocking leukotriene receptors.
Supported by 12.1 Mechanism of Action (binds with high affinity/selectivity to CysLT1 receptor; inhibits LTD4 actions).
Montelukast reduces bronchoconstriction.
Supported indirectly by 1.2 EIB prevention and 12.1 mechanism (leukotriene-mediated effects including smooth muscle contraction).
Montelukast is used for asthma maintenance to help prevent symptoms.
Supported by 1.1 Asthma (prophylaxis and chronic treatment).
Montelukast is used for exercise-induced bronchoconstriction.
Supported by 1.2 Exercise-Induced Bronchoconstriction (EIB) prevention.
Montelukast is used for allergic rhinitis (seasonal allergies) in some patients.
Supported by 1.3 Allergic Rhinitis (relief of seasonal allergic rhinitis symptoms in patients ≥15 years).
Unsupported Statements
Montelukast is not an antibiotic.
The provided label excerpts do not explicitly state montelukast is or is not an antibiotic.
Montelukast is a prescription medicine.
No provided label excerpt states prescription-only status.
Montelukast is used to treat allergies.
Label excerpt supports allergic rhinitis specifically, not a general 'allergies' statement.
Montelukast reduces inflammation.
Mechanism describes leukotriene-mediated effects (e.g., airway edema, smooth muscle contraction) but the provided excerpts do not explicitly state 'reduces inflammation.'
Montelukast helps with breathing symptoms.
The provided excerpts support asthma/EIB indications, but do not explicitly state 'breathing symptoms.'
Montelukast does not kill bacteria.
No provided label excerpt addresses antibacterial or killing bacteria activity.
Montelukast has no role in treating bacterial infections.
No provided label excerpt addresses bacterial infections or montelukast's role in them.
Montelukast is not for bacterial infections.
No provided label excerpt explicitly states non-indication for bacterial infections.
Montelukast is not a substitute for antibiotics when antibiotics are needed for pneumonia or strep throat.
No provided label excerpt mentions pneumonia, strep throat, antibiotics, or substitution guidance.
For viral illnesses, antibiotics generally do not help.
No provided label excerpt discusses viral illnesses or antibiotic effectiveness.
Contradictions
Important Omissions
No evaluation possible for label safety-critical content (e.g., boxed warnings, contraindications, dosing/administration instructions, drug interactions, and monitoring) because only Indications and Mechanism excerpts were provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about antibiotic/non-antibiotic use and bacterial infection management could be misleading; however, the core labeled indication/mechanism claims are generally consistent with provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple antibiotic-related assertions are not supported by the supplied FDA label excerpts.
Suggested Improvement
Restrict claims to the provided label-supported indications (asthma prophylaxis/chronic treatment, EIB prevention, allergic rhinitis symptom relief) and the mechanism (CysLT1 receptor binding/inhibition of LTD4 actions); remove or qualify antibiotic/bacterial infection statements unless supported by additional label sections.